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369 pp. $29.00In the United States, rare diseases are
defined as conditions affecting fewer
than 200,000 individuals at any given
time. Worldwide, an estimated 300 million
people are affected by rare diseases, also
known as ‘‘orphan diseases’’ because
with few financial incentives for devel-
oping new treatments, the pharmaceu-
tical industry did not ‘‘adopt’’ them. In
his book entitled Orphan, Phillip Reilly
paints a picture of several rare diseases
and the quest to find treatments for them.
Recent years have witnessed a sea
change in attention to rare diseases due
to the convergence of regulatory, scienti-
fic, and societal forces. In 1983, the US
Congress enacted the Orphan Drug Act
(ODA), providing a number of incentives
for companies to work on rare diseases.
In addition, the blockbuster drug model
focusing on common, highly profitable
conditions such as hypertension or hyper-
cholesterolemia proved to be unsustain-
able for the pharmaceutical industry.
Many companies have instead turned to
rare diseases, especially those that are
genetic in origin and have a well-charac-
terized biological mechanism. Finally,
the technologies necessary to intervene
in genetic disorders are starting to
mature, enabling a number of therapeutic
options. It is amidst this synergistic set of
circumstances that Reilly’s book arrives,
describing the advances for some of
these disorders, the heroes (parents, sci-
entists, clinicians, companies) behind
these advances, and the work left to be
done.
Reilly brings a broad and unique
perspective on these disorders to his
book. With both MD and JD degrees to
his credit and board certification in Inter-
nal Medicine and Clinical Genetics, he
joined the Eunice Kennedy Shriver Center
for Mental Retardation in the mid-1980s.
There, he provided primary care for 800
adults in a state-run institution for people
with severe neurological conditions. He786 Cell 163, November 5, 2015 ª2015 Elsevthen joined a venture capital firm in 2008
and has been focusing on starting com-
panies to treat rare genetic disorders.
This wide range of experiences allows
him to move with relative ease between
describing the impact of these disorders
on individuals and their families to discus-
sing the societal and economic impacts of
decisions surrounding these conditions.
His work as a physician, geneticist, and
venture capitalist, together with his
evident interest in history of medicine,
contribute to his narrative of the thrilling
advances in the area of rare diseases
and how they have touched people’s
lives.
Reilly observes, ‘‘To build a company
with the goal of developing a novel, trans-
formative therapy for an orphan genetic
disorder one must understand the disor-
der and its impact on families at a level
that can never be attained simply by
reading medical journals.’’ Accordingly,
Orphan is full of stories about individuals
Reilly has gotten to know under variousier Inc.circumstances. The most vivid vignettes
are those of families affected with rare
diseases such as phenylketonuria (PKU),
a disease that has come under control
with dietary treatments; dystrophic epi-
dermolysis bullosa, a life-threatening
skin condition; and X-linked adrenoleuko-
dystrophy, a neurological disorder pre-
senting with cognitive decline in elemen-
tary school years. Since 50% of the
people affected by rare diseases are chil-
dren, many of the vignettes highlight their
parents. Parents have made enormous
contributions to the advances in rare dis-
ease treatment by being advocates,
lobbyists, and entrepreneurs—but above
all, courageous caregivers willing to enroll
their children in phase I or II clinical trials.
Other heroes in the book are physicians
and scientists who focus on a rare disor-
der and make it their career to seek a
treatment. One distinguished example
among many is Roscoe Brady, a physi-
cian scientist and outstanding biochemist
at the National Institute of Neurological
Disorders and Stroke (NINDS). Brady
focused on Gaucher disease, a disorder
in which the lipid glucocerebroside accu-
mulates in the body, leading to liver and
spleen enlargement. Brady and col-
leagues discovered that the synthesis of
this lipid was normal, but its clearance
by a key lysosomal enzyme was impaired
in people with Gaucher disease. In 1966,
20 years before the gene encoding this
enzyme was cloned, Brady proposed
treating Gaucher patients with enzyme
replacement, but it was not until 1991
that the success of such an approach
was demonstrated in a clinical trial using
enzyme extracted from placentas. Since
then, a recombinant protein replacement
approach has been used effectively to
treat a number of diseases of lysosomal
enzyme deficiency.
Over the last two decades, similar ap-
proaches have been approved for a num-
ber of rare diseases, but patients must
take these medications regularly for the
rest of their lives. Newer approaches us-
ing gene therapy are trying to change
that, and Reilly discusses the ups and
downs of this research in detail. Gene
therapy is experiencing a renaissance fu-
eled by advances in viral vector technol-
ogy and is being tested in many ongoing
clinical trials, including for rare diseases
such as spinal muscular atrophy, the
leading genetic cause of infant mortality.
To date, only one gene therapy product
(Glybera, a drug to treat a rare lipid disor-
der) is approved in Europe; none are
approved in the US. Nonetheless, there
is great promise for viral-mediated gene
delivery to turn diseases with high mortal-
ity into chronic conditions.
In addition to viral gene delivery, other
technologies are likely to expand thera-
peutic possibilities, reduce side effects,
and improve efficacy in rare diseases. Re-
illy summarizes these advancements,
such as exon skipping, RNA interference,
induced pluripotent stem cells, and gene
editing. According to a 2013 American
Biopharmaceutical Research Companies
report, more than 450 drugs are in devel-
opment for rare diseases. While this is un-
doubtedly significant progress, there are
still scientific, regulatory, and economic
hurdles to drug development for rare dis-
eases. One major scientific obstacle re-
mains the blood-brain barrier, which is
impenetrable to many small molecules
and almost all biologicals. Given that
many rare genetic diseases affect the ner-
vous system, technologies that can tra-
verse the blood-brain barrier are a high
priority. In addition, for many diseases,
we still do not know how early treatment
must be initiated to be effective, so
defining the temporal windows critical
for treatment is a major challenge. More-
over, clinical trials may be difficult to
design for rare diseases due to small pa-
tient populations, variability of expres-
sion, and lack of validated endpoints,
especially for those affecting the central
nervous system. These hurdles can be
further complicated by diverse mutationsin the same disease gene that sometimes
require different treatments, as exempli-
fied by recent treatments developed for
cystic fibrosis patients carrying only
certain mutations. While we have reason
to be enthusiastic about the promise of
mechanism-based treatments, we need
to be realistic about these challenges so
that we can overcome them.
‘‘We are all orphans’’ is the provocative
title of Reilly’s final chapter. Copy-number
variants and whole-exome analysis
studies have revealed that each one of
us carries rare changes in our genome
that could affect our health. For many of
them, we do not yet know whether there
is any clinical significance, but some com-
mon diseases will likely be caused by a
combination of genetic variants, as we
are discovering for autism spectrum dis-
order. Highly penetrant genetic variations
may contribute to some of the more than
7,000 diseases that are considered rare
diseases, affecting an estimated 20–30
million Americans. The Precision Medi-
cine Initiative put forth by President Ob-
ama may therefore have the largest initial
impact on rare diseases.
Reilly acknowledges the societal,
ethical, and financial considerations in
this era of huge progress in rare disease
research and treatment. Increased detec-
tion during gestation and the potential
necessity of treatment at fetal stages
raise major ethical issues. As genetic
diagnosis technology improves, there
will be increased demand for Masters-
level trained genetic counselors, who are
already scarce in our healthcare system.
As effective therapies become available,
there will be fewer reasons to deny ge-Cell 163,netic diagnostic tests to patients. More-
over, the high cost of certain approved
treatments has already attracted atten-
tion. Some of the newer therapies will
turn chronic costs into large one-time
treatment costs. How will such costs be
reimbursed? What will the impact be in
the developing world? Currently, it is esti-
mated that a quarter of the beds in pediat-
ric hospitals are occupied by patients with
genetic diseases. As a child neurologist
investigating some of these rare diseases,
I suspect that number is underestimated,
not accounting for many undiagnosed ge-
netic disorders.
‘‘This book is about the struggle to
save the lives of children who, because
of a roll of the genetic dice, are born
with any one of the more than several
thousand rare genetic disorders.’’ In
Orphan, Reilly skillfully describes the
promise and challenges of treating rare
diseases and encourages public
discourse about where we can be in the
next few decades. The book will likely
engage not only those working on or
affected by rare diseases, but also stu-
dents and biomedical scientists broadly.
Different readers may be drawn to
different aspects of the book: resilience
of the individuals and families living with
these conditions, progress in basic sci-
ence and technology, or the due dili-
gence process for a startup company. A
combination of our resources, participa-
tion from families, hard work from physi-
cians and scientists, and the support of
industry and funders will be needed to
translate genetic discoveries into treat-
ments that will improve the lives of those
touched by rare diseases.Mustafa Sahin1,*
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